Trial intelligence / Profile preview

GFH009 plus zanubrutinib in relapsed/refractory DLBCL (Ib/II, single-arm, open-label, multicenter)

CTR20240475Phase 2Active

Sponsor

GenFleet Therapeutics

Start

Mar 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1